Drug Trial Radar · NCT07389473
Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 17, 2024
Primary completion
Dec 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- GaizeIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.
Conditions
- ADHD
- Depression Disorders
- Mood Disorders
- Anxiety Disorder Generalized
- Bipolar Disorder (BPD)
Interventions
Prescription Psychotropic MedicationsDrug
Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Collection of Ophthalmic DataTime frame: 1 Day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gaize
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.